Jim Cramer Notes Pfizer (PFE) Has “Got a Lot of Stuff in the Pipeline” [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pfizer was not relevant for the AI theme, when a caller inquired about the stock, Cramer said: Okay… Pfizer is not an espresso. Pfizer is more like Nescafé, but that's okay. It's at $26. It yields 6.4%. It's got a lot of stuff in the pipeline. Photo by Spencer Davis on Unsplash Pfizer Inc. (NYSE:PFE) develops and sells medicines and vaccines for several health conditions, including heart disease, infections, COVID-19, and rare diseases. Cramer talked about the stock during the Squawk on the Street episode aired on January 12, as he commented: Pfizer, you know, principal vaccine company in the country. I think we have to accept Carl that the vaccine business is under fire. I don't think that Dr. Bourla is ready for a fight with RFK Jr. I think RFK Jr. wins on this. Let's see what Pfizer has to say, cause they actually have a lot of important vaccines that maybe should be called into question. While we acknowledge the potential of PFE as an investment, we believe certain AI st
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook [Yahoo! Finance]Yahoo! Finance
- Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLCBusiness Wire
- Pfizer aims for wider use of PARP drug in prostate cancer with new data [Yahoo! Finance]Yahoo! Finance
- The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients [Fortune]Fortune
- TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate CancerBusiness Wire
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/16/26 - Form 4
- 3/12/26 - Form ARS
- 3/12/26 - Form DEFA14A
- PFE's page on the SEC website